The effect of cathepsin K inhibitor on osteoclastic activity compared to alendronate and enamel matrix protein.
OBJECTIVE
There have been several attempts to treat delayed replantation with agents that inhibit root resorption. The purpose of this study was to assess the effectiveness of cathepsin K inhibitor in inhibiting osteoclastic activity compared to that of alendronate and enamel matrix protein.


METHODS
Murine RAW 264.7 cells were cultured in the presence of the receptor activator of NF-kB and lipopolysaccharide, followed by treatment with odanacatib, alendronate, or Emdogain at various concentrations. After drug treatment, an MTT assay was performed to evaluate cytotoxicity, while reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assays were performed to determine the expression levels of interleukin-1β, interleukin-6, prostaglandin E2, and tumor necrosis factor-α. Data were analyzed by one-way anova and Tukey's post-hoc test (P < 0.05).


RESULTS
Of all tested agents, Emdogain resulted in the least cytotoxicity on RAW 264.7 cells, while 10(-9) M odanacatib had the largest suppressive effects on the expression levels of inflammatory cytokines.


CONCLUSIONS
Odanacatib inhibits osteoclastic activity, showing the possibility as a treatment agent for delayed replantation of avulsed teeth.
Department of Conservative Dentistry, Ulsan University, Asan Medical Center, Seoul, Korea.
Wonkyung
W
Yang
Hyunjung
H
Ko
Heesun
H
Kim
Miri
M
Kim
D019386:Alendronate / Q000494:pharmacology*; D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D056657:Cathepsin K / Q000037:antagonists & inhibitors*; D002478:Cells, Cultured; D003746:Dental Enamel Proteins / Q000494:pharmacology*; D015232:Dinoprostone / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides; D051379:Mice; D010010:Osteoclasts / Q000187:drug effects*; D053245:RANK Ligand / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D001713:Biphenyl Compounds; D003746:Dental Enamel Proteins; D053583:Interleukin-1beta; D015850:Interleukin-6; D008070:Lipopolysaccharides; D053245:RANK Ligand; D014409:Tumor Necrosis Factor-alpha; C109069:enamel matrix proteins; D056657:Cathepsin K; D015232:Dinoprostone; C527128:odanacatib; D019386:Alendronate
aulsion; cathepsin K inhibitor; osteoclast; replantation